Aspira Women's Health Inc. (AWHL)
AWHL is quoted over the counter, not listed on an exchange. Aspira Women's Health Inc. files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.
Closes: Yahoo Finance daily closes, last bar 2026-11-16.
Profile
| Field | Value |
|---|---|
| Ticker | AWHL, quoted over the counter |
| SEC CIK | 0000926617 |
| OTC Markets tier | OTCQX (price source, 2026-11-13) |
| SEC industry code | In Vitro & In Vivo Diagnostic Substances |
| Business address | Austin, TX |
| Incorporated in | DE |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "Given the above conditions, there is substantial doubt about the Company's ability to continue as a going concern within one year after the date these consolidated interim financial statements are issued." | 10-Q 2026-08-14 |
| Cash and burn | $477K cash; operating cash flow -$1.1M a quarter. | Report 2026-06-30 |
| Shares outstanding | 46,633,744 (2026-08-12); 35,655,918 a year earlier; 10,198,341 three years earlier. | Cover page 2026-08-12 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | BDO USA, P.C., Boston, Massachusetts, United States | PCAOB Form AP 2026-04-02 |
| Late filings, 12 months | 1 NT notice | NT 10-K 2026-04-01 |
| Insider trades, 12 months | Bought $100K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $17K | -$2.4M | -$2.0M | $477K | $1.7M | $170K | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | $32K | $676K | -$359K | $1.3M | $3.1M | $322K | 10-Q 2026-05-15 |
| Q4 2025 2025-12-31 | $32K | -$3.4M | -$2.0M | $1.8M | $1.8M | $290K | 10-K 2026-04-01 |
| Q3 2025 2025-09-30 | $89K | -$4.9M | -$212K | $3.8M | $1.3M | $2.6M | 10-Q 2025-11-14 |
| Q2 2025 2025-06-30 | $169K | -$2.7M | -$1.7M | $1.5M | $1.5M | $4.8M | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | $0 | -$1.9M | -$3.1M | $3.3M | $1.8M | $7.0M | 10-Q 2026-05-15 |
| Q4 2024 2024-12-31 | $2.3M | -$1.4M | -$1.0M | $1.8M | $2.1M | $9.2M | 10-K 2026-04-01 |
| Q3 2024 2024-09-30 | $2.3M | -$3.5M | -$2.9M | $2.1M | $1.6M | $86.8M | 10-Q 2025-11-14 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-01-12 |
| Latest annual report | 10-K | 2026-04-01 |
| Latest quarterly / interim | 10-Q | 2026-11-16 |
| Latest current report | 8-K | 2026-11-16 |
| Latest proxy | DEFA14A | 2026-05-29 |
Source: SEC EDGAR submissions feed, 1,002 recent filings. All filings on EDGAR.
The full dossier has every filing, quarterly and annual financials, the health record and a price chart.
Open the full dossier